NGS – a weapon in molecular pathology?
Next generation sequencing has revolutionised cancer management, but has also raised some issues that have yet to be addressed
A study reveals the clonal heterogeneity of de novo metastatic castration-sensitive prostate cancer
Findings suggest that analysis of multiple prostate diagnostic biopsy cores, in contrast to frequent practice, may help reduce tumour mischaracterisation and identify genetic alterations relevant to personalised treatment
Combining liquid biopsy technologies may help improve tumour monitoring
Results from two studies suggest that this approach is essential to refining liquid biopsy use in early cancer detection and to check tumour progression
Should cancer therapy be tailored based on receptor tyrosine kinase alterations?
Data from a molecular analysis of receptor tyrosine kinase-mutated cancers show a wide heterogeneity of alterations and response to tyrosine kinase inhibitor monotherapy
Improving the efficacy of engineered T-cells – from gene transfer to genome editing
A new level of sophistication, namely genome editing, is now available to help overcome previous hurdles with adoptive T-cell therapies
New targets for off-the-shelf treatments open up the field of precision immunotherapy
The identification of mutation-derived neoantigens may help elicit antitumour immune responses in patients with cancer, but this approach is challenging